Lack of postmenopausal estrogen replacement therapy and the risk of dementia.

Estrogen replacement therapy (ERT) and associated risks for ischemic vascular dementia (IVD) and dementia of the Alzheimer's type (DAT) among postmenopausal women were investigated by determining whether ERT was differently distributed among control subjects than among subjects with dementia. Subjects included 93 with probable DAT, 65 with probable IVD, and 148 normal control subjects. The proportion of control subjects on ERT was almost 2:1, and this ratio holds for both dementia groups. Logistic regression suggests lack of ERT is associated with increased risk for dementia among elderly women. ERT may eventually prove to be a useful prophylactic agent for reducing risk of DAT and IVD among postmenopausal women.

[1]  K. Mortel,et al.  Analysis of Familial and Individual Risk Factors Among Patients with Ischemic Vascular Dementia and Alzheimer's Disease , 1993, Angiology.

[2]  S. Cummings,et al.  Association Between Low Bone Density and Stroke in Elderly Women: The Study of Osteoporotic Fractures , 1993, Stroke.

[3]  David C. Atkins,et al.  A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. , 1993, Archives of internal medicine.

[4]  E. Barrett-Connor,et al.  Estrogen replacement therapy and cognitive function in older women. , 1993, JAMA.

[5]  J. Bar,et al.  The Effect of Estrogen Replacement Therapy on Platelet Aggregation and Adenosine Triphosphate Release in Postmenopausal Women , 1993, Obstetrics and gynecology.

[6]  J. Madans,et al.  Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. , 1993, Archives of internal medicine.

[7]  H. Kuhl.  [Hormonal contraception and substitution therapy: the importance of progestogen for cardiovascular diseases]. , 1992, Geburtshilfe und Frauenheilkunde.

[8]  B. Sherwin,et al.  Effects of estrogen on memory function in surgically menopausal women , 1992, Psychoneuroendocrinology.

[9]  J. Neaton,et al.  Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology? , 1992, The Lancet.

[10]  F. Sohrabji,et al.  Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[12]  W. Jagust,et al.  Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers , 1992, Neurology.

[13]  M. Kawata,et al.  Estrogen as a growth factor to central nervous cells Estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  K. Mortel,et al.  Effects of Estrogen Replacement Therapy on Cerebral Perfusion and Cognition among Postmenopausal Women , 1991 .

[15]  R. Lobo,et al.  Estrogen Improves Psychological Function in Asymptomatic Postmenopausal Women , 1991, Obstetrics and gynecology.

[16]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[17]  T. Hillard,et al.  THE LONG‐TERM RISKS AND BENEFITS OF HORMONE REPLACEMENT THERAPY , 1991, Journal of clinical pharmacy and therapeutics.

[18]  C. Woolley,et al.  Steroid hormones as mediators of neural plasticity , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  E. Barrett-Connor,et al.  Estrogen and coronary heart disease in women , 1991, JAMA.

[20]  H. Morgenstern,et al.  Women, myocardial infarction, and dementia in the very old , 1990, Neurology.

[21]  R. Lobo.  Cardiovascular implications of estrogen replacement therapy. , 1990 .

[22]  P. Henriksson,et al.  Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation , 1990, European journal of clinical investigation.

[23]  B. Sherwin,et al.  A Prospective One-Year Study of Estrogen and Progestin in Postmenopausal Women: Effects on Clinical Symptoms and Lipoprotein Lipids , 1989, Obstetrics and gynecology.

[24]  B. Sherwin,et al.  Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women , 1988, Psychoneuroendocrinology.

[25]  B. Henderson,et al.  Postmenopausal oestrogen treatment and stroke: a prospective study. , 1988, BMJ.

[26]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[27]  E. Barrett-Connor,et al.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. , 1987, Circulation.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[29]  O. Ylikorkala,et al.  Urinary excretion of prostacyclin and thromboxane metabolites in climacteric women: effect of estrogen-progestin replacement therapy. , 1990, Prostaglandins.